3U9Y
Crystal structure of human tankyrase 2 catalytic domain in complex with olaparib
Summary for 3U9Y
Entry DOI | 10.2210/pdb3u9y/pdb |
Related | 3U9H 3UA9 |
Descriptor | Tankyrase-2, ZINC ION, SULFATE ION, ... (6 entities in total) |
Functional Keywords | protein-ligand complex, diphtheria toxin like fold, adp-ribosylation, transferase-transferase inhibitor complex, transferase/transferase inhibitor |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 1 |
Total formula weight | 28083.86 |
Authors | Narwal, M.,Lehtio, L. (deposition date: 2011-10-20, release date: 2012-01-25, Last modification date: 2023-09-13) |
Primary citation | Narwal, M.,Venkannagari, H.,Lehtio, L. Structural basis of selective inhibition of human tankyrases. J.Med.Chem., 55:1360-1367, 2012 Cited by PubMed Abstract: Tankyrases are poly(ADP-ribose) polymerases that have many cellular functions. They play pharmaceutically important roles, at least in telomere homeostasis and Wnt signaling, by covalently ADP-ribosylating target proteins and consequently regulating their functions. These features make tankyrases potential targets for treatment of cancer. We report here crystal structures of human tankyrase 2 catalytic fragment in complex with a byproduct, nicotinamide, and with selective inhibitors of tankyrases (IWR-1) and PARPs 1 and 2 (olaparib). Binding of these inhibitors to tankyrase 2 induces specific conformational changes. The crystal structures explain the selectivity of the inhibitors, reveal the flexibility of a substrate binding loop, and explain existing structure-activity relationship data. The first crystal structure of a PARP enzyme in complex with a potent inhibitor, IWR-1, that does not bind to the widely utilized nicotinamide-binding site makes the structure valuable for development of PARP inhibitors in general. PubMed: 22233320DOI: 10.1021/jm201510p PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.3 Å) |
Structure validation
Download full validation report